Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up

Kolibianakis, Efstratios M.; Bourgain, Claire; Albano, Carola; Osmanagaoglu, Kaan; Smitz, Johan; Steirteghem, André Van; Devroey, Paul

doi:10.1016/s0015-0282(02)03323-x

Cited by 320 publications

(203 citation statements)

References 17 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, increasing age was a strong determinant of decreasing implantation. In another study by Kolibianakis et al, increasing the FSH dose alone at the time of GnRH-antagonist initiation was not associated with improved pregnancy outcomes [14]. In addition, this approach seemed not to improve endometrial maturity as assessed by histologic examination.…”

Section: Discussionmentioning

confidence: 92%

Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes

Detti

Ambler

Yelian

et al. 2008

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To evaluate whether oocyte quality, implantation and pregnancy outcomes in in vitro fertilization (IVF)/ intra-cytoplasmic sperm injection (ICSI) are related to the duration of gonadotropin-releasing hormone (GnRH)-antagonist use or the timing of its initiation. Methods Retrospective cohort study of 178 conventional IVF/ICSI cycles. All patients underwent ovarian stimulation with gonadotropins and GnRH-antagonist for pituitary down-regulation. Spearman correlations and logistic regression were used for statistical analysis. Results There was no correlation between the duration of use or the timing of initiation of GnRH-antagonist with oocyte quality or implantation and pregnancy outcomes. Oocyte quality was influenced by the peak estradiol. Implantation was influenced by the patient's age. Early pregnancy loss, by the endometrial thickness on human chorionic gonadotropin-day. Ongoing pregnancy was independent from the variables evaluated.Conclusions GnRH-antagonist duration of use or starting day did not influence oocyte quality, implantation rates, and pregnancy rates. We hypothesize that a follicle stimulating hormone/luteinizing hormone dose increase when antagonist was started, may have had an impact on our findings.

show abstract

Section: Discussionmentioning

confidence: 92%

Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes

Detti

Ambler

Yelian

et al. 2008

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…This has been demonstrated in endometrial biopsies taken before hCG injection, and therefore before exposure to progesterone (57). When the endometrium has been sampled on the day of oocyte retrieval, it has shown advancement in a high proportion of both agonist (58) and antagonist cycles (59). If advancement exceeds 3 days, pregnancy is unlikely (60).…”

Section: Endometrial Receptivitymentioning

confidence: 99%

GnRH analogues: applications in assisted reproductive techniques

Hayden

2008

European Journal of Endocrinology

View full text Add to dashboard Cite

The ability to prevent an endogenous LH surge revolutionised the efficacy of assisted reproductive techniques (ART) such that GnRH agonists were rapidly adopted in the 1980s. Prior to this, premature luteinisation occurred in up to 25% of superovulated cycles leading to cycle cancellation and severely compromised outcomes. Analogues have been applied in a variety of drug protocols (long, short flare) but there has been little research to moderate the degree of pituitary suppression. There has also been ongoing and unresolved debate about the role of LH in supporting follicular development.By 2001, the first GnRH antagonists were registered for use in ART. Their ability to cause immediate suppression of gonadotrophin (particularly LH) secretion means that they can be given after exogenous stimulation has begun and thereby dramatically shorten the total duration of a treatment cycle. After initial enthusiasm and then scepticism that pregnancy rates may not be as high as the established agonist regimens, these preparations are now being increasingly adopted with at least comparable outcomes in large trials. They are certainly favoured by patients for their reduced side-effect profile and particularly for the shortening of the total cycle length. This shift in practice is occurring alongside gathering momentum in favour of milder stimulation protocols and a new perception of what constitutes successful treatment. The focus is moving away from surrogate outcomes such as oocyte numbers and conception rates towards long-term outcomes for women and their offspring, namely the achievement of a live singleton birth per treatment started.

show abstract

“…Although cryopreservation may entail some risks to the embryo, FET may provide an endometrium with increased receptivity, as compared to that after ovarian stimulation. The timing of the Bwindow of implantation( WOI) in stimulated cycles is complicated by the fact that it may be advanced or delayed, and therefore easily mistimed [15][16][17][18][19][20][21][22]. Shapiro et al [23] showed that the clinical pregnancy rate per transfer is significantly greater in the cryopreservation group than in the fresh group in normal responders and concluded that the difference was due to impaired endometrial receptivity in fresh embryo transfer.…”

Section: Introductionmentioning

confidence: 99%

Optimal embryo transfer strategy in poor response may include freeze-all

Berkkanoğlu

Coetzee

Bulut

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose In this retrospective cohort study, we investigated the best embryo transfer strategy in ICSI cycles with ≤4 oocytes collected at oocyte retrieval. Methods Women who underwent antagonist co-treatment COS for ICSI treatment between January 2010 and December 2015 at a private ART clinic (N = 2263). Eight hundred seventy-nine women (group 1) had ≤4 oocytes collected at oocyte retrieval, of whom 645 (group A) had cleavage stage embryo transfer (ET), and 234 (group B) had blastocyst ET. One thousand three hundred eighty-four women (group 2) had 10-15 oocytes collected at oocyte retrieval, of whom 676 (group C) had cleavage stage ET, and 708 women (group D) had blastocyst ET. Blastocyst vitrification was performed using the Cryotop method and FET using artificial cycles. Results In group 1, the cancellation rate was significantly lower in group A (25.2 vs 38 %). The pregnancy rate (PR), clinical PR, implantation rate (IR), and live birth rate (LBR) per ET and per oocyte retrieval were all lower in group A. The clinical PR, IR, and LBR per ET of vitrified-warmed blastocyst ET were significantly the highest. In group 2, the cycle cancellation rate was significantly lower in group C (3.5 vs 13.4 %). The PR, clinical PR, and IR per ET and per oocyte retrieval were all lower in group C. The LBR per ET was significantly lower, but the LBR per oocyte retrieval was not significantly lower in group C. Again, the PR, clinical PR, and IR per ET of vitrifiedwarmed blastocyst ET were significantly the highest. Conclusions Day 5 ET strategy has been reserved for normal or high responders. The improved pregnancy outcomes from blastocyst culture and cryopreservation may challenge ART to extend this benefit to poor responders.

show abstract

Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up

Cited by 320 publications

References 17 publications

Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes

Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes

GnRH analogues: applications in assisted reproductive techniques

Optimal embryo transfer strategy in poor response may include freeze-all

Contact Info

Product

Resources

About